Myelodysplastic Syndrome Clinical Trial
Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Summary
The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Eligibility Criteria
Inclusion Criteria:
Adults with primary or secondary relapsed and/or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Detectable levels of cluster of differentiation 33 (CD33) expression.
Failed alternative therapies with established benefit.
Eastern Cooperative Oncology Group (ECOG) performance status ≤2 and adequate organ function.
Exclusion Criteria:
Acute Promyelocytic Leukemia.
Clinically active central nervous system leukemia.
Active malignant solid tumor.
Pregnant or breastfeeding.
Other protocol-defined inclusion/exclusion criteria apply.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 10 Locations for this study
Boston Massachusetts, 02114, United States
Saint Louis Missouri, 63110, United States
New York New York, 10032, United States
Fairfax Virginia, 22031, United States
How clear is this clinincal trial information?
